Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474760 · ClinicalTrials.gov registry record · Phase 1
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00474760 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 65 participants.
The verdict
NCT00474760, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).
Interventions
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2005-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474760
The ClinicalTrials.gov registry entry for NCT00474760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-751,871 is the first listed.
NCT00474760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474760 about?
NCT00474760 is a clinical study titled "Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors". This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).
What is the current status of trial NCT00474760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2005-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00474760?
The interventions under investigation include: CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00474760?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.